Aster DM Quality Care Q2 results: revenue Rs 2,829 crore, normalised PAT Rs 281 crore
Aster DM Quality Care Q2 results: normalised PAT was Rs 281 crore, up 34%, on revenue of Rs 2,829 crore, first quarter after the merger.
Aster DM Quality Care Q2 results: the company reported a consolidated profit attributable to owners of Rs 262.02 crore for the second quarter of FY27 (July-September 2026), against Rs 110.00 crore a year earlier, according to its exchange filing of 6 November 2026. The company also reported normalised profit after tax of Rs 281 crore, up 34%. This is the first quarter in which the company reports as the combined Aster and CARE hospitals group, which began operating as one entity on 1 July 2026.
Aster DM Quality Care Q2 results: key numbers
| Measure (Rs crore, consolidated) | Q2 FY27 | Q2 FY26 |
|---|---|---|
| Revenue from operations (statutory) | 2,829.20 | 1,197.21 |
| Profit before tax | 419.35 | 166.85 |
| Profit for the period (before minority share) | 322.38 | 121.31 |
| Profit attributable to owners | 262.02 | 110.00 |
| Exceptional items (expense) | 18.95 | 0.36 |
Why two sets of numbers differ
The statutory figures compare the merged company with the pre-merger Aster business of last year, so revenue appears to more than double. The company’s press release instead says revenue grew 19% to Rs 2,829 crore and normalised profit after tax rose 34% to Rs 281 crore. Normalised profit leaves out merger-related costs. Where figures differ, we have used the exchange filing for the table and the company’s own wording for its growth rates.
Why profit rose
Per a news report of the company’s commentary, EBITDA was Rs 664 crore against Rs 250 crore, with margin of 23.5%. Management attributed this to higher patient footfall, more complex procedures and a favourable payor mix. Patient volumes grew 12% in the quarter. The company said its newer hospitals, including Kasargod and Nagercoil, grew 61%.
One-time items
The filing shows Rs 18.95 crore of merger-related professional fees and other costs in Q2, shown as an exceptional item. For the six months to September, these costs were Rs 133.33 crore.
What to watch next
Executive Chairman Dr Azad Moopen said the company completed its first 100 days as a combined entity and is progressing the Aster Trivandrum project towards commissioning. Follow more hospital earnings in our results news section.
Frequently asked questions
Why does reported revenue growth look much higher than 19%?
The statutory comparison with Q2 FY26 shows revenue more than doubling because the merged entity began operating as one on 1 July 2026. The company's 19% growth refers to a comparison it presents as like-for-like.
This article is a summary for information only and is not investment advice. Figures are as reported by the sources above; please verify with the original filing or report before making any decision.
More Results News
See all →- Honasa Consumer Q2 results: revenue up 36% to Rs 731 crore, EBITDA nearly doubles to Rs 93 crore
- Coromandel International Q2 results: profit falls 33% on fertiliser margin pressure
- Gland Pharma Q2 results: consolidated profit rises 58% and revenue 23% on US and CDMO growth
- Chambal Fertilisers declares Rs 5 interim dividend; Q2 standalone profit up 6% to Rs 635 crore
- Balkrishna Industries Q2 results: profit up 10% on 46% higher revenue; Rs 4 dividend record date 11 November